Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | BCL9 | O00512 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4237866 | 0.91 | MAOB (0.40) | TBXA2RALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4233545 | 0.88 | TDP2 (0.47) | TBXA2RALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4240320 | 0.88 | ALDH1A1 (0.42) | TBXA2RALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4232035 | 0.88 | MAPT (0.46) | TBXA2RALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4227934 | 0.87 | HSPB1 (0.53) | TBXA2RALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4237809 | 0.87 | PDE7A (0.54) | TBXA2RALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4238971 | 0.87 | TTR (0.48) | TBXA2RALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4238047 | 0.87 | TBXA2R (0.48) | TBXA2RALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4236941 | 0.85 | HSPB1 (0.40) | TBXA2RALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4238193 | 0.85 | MEN1 (0.46) | ALDH1A1MAPTMEN1KMT2ABCL9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | TBXA2R 193/4885ALDH1A1 4542/4885MAPT 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.